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Thrombotic Thrombocytopenic Purpura Revisited:
Upshaw Schulman Syndrome in a 20-Year-Old Male
Judy Wang, MD and Niluk Peiris, MD

Case Report
A 20-year-old male with no significant past medical history
presented to an outside hospital with a two-week history of
progressive fatigue, malaise and decreased appetite. Prior to
these events, he had been in his usual state of health with normal
exercise tolerance and energy level. Upon development of his
symptoms, the patient felt as though he had developed an upper
respiratory infection (URI). The URI symptoms eventually
resolved; however complaints of fatigue and malaise still
remained. He then developed progressive dyspnea on exertion
and tea-colored urine. The patient reported a singular febrile
episode to 38.9˚C associated with nonbilious vomiting two days
prior to admission. Upon further questioning, he admitted to
a twenty-pound weight loss over the last month. The patient’s
mother also noticed unprovoked bruising on his forearms
bilaterally. He denied night sweats, gingival bleeding, epistaxis,
hematuria, or melena.
The patient is of Afro-Jamaican descent; his family originating
from Trinidad. He reported no family history of hematologic
disorders, and only acknowledged a maternal grandmother
with breast cancer. The patient denied chronic medications,
including herbal and over-the-counter medications. He denied
food or drug allergies, as well as alcohol, tobacco or illicit drug
use. He reported being sexual active with one partner in the past
6 months and denied any sexually transmitted infections.

Hospital Course
On admission to the outside hospital, laboratory results
revealed a profound anemia (hemoglobin 6.3 g/dL) with an
elevated red cell distribution width (RDW) (22.4%), thrombocytopenia (platelet count 44 B/L) and acute kidney injury
(serum creatinine 1.9 mg/dL). Subsequent testing reported
the presence of 4+ schistocytes on peripheral blood smear
concerning for microangiopathic hemolytic anemia (MAHA).
Given his triad of anemia, thrombocytopenia and presence of
schistocytes, there was a concern for thrombotic thrombocytopenic purpura (TTP). He was transferred to our institution
for further management. Prior to transfer, the patient was
medically supported with blood products and underwent a bone
marrow biopsy that was determined to be non-malignant.
Upon arrival to our institution, further laboratory results
revealed a significantly elevated lactate dehydrogenase (LDH)
(956 IU/L) with essentially undetectable haptoglobin (<10 mg/
dL). Urinalysis was positive for 2+ protein and 1+ blood. Direct
Coombs test was negative. Repeat peripheral blood smear was
positive for the presence of 3+ schistocytes, confirming concern
for TTP. The patient was transferred to the medical intensive
care unit and immediately started on intravenous methylpred-
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nisolone, folate, and blood products until an apheresis catheter
could be placed for plasma exchange therapy. Once the catheter
was placed, the patient underwent five sessions of plasma
exchange therapy without complications. Human immunodeficiency virus (HIV) antibody, hepatitis B and C serologies
were negative. His steroids were tapered, and blood counts and
LDH were monitored daily. Upon discharge, hemoglobin had
increased to 8.2 mg/dL, RDW 20.3%, platelet count 259 B/L,
and LDH 263 IU/L. Haptoglobin had increased to 46 mg/dL and
serum creatinine had improved to 0.8 mg/dL. A Disintegrin-like
And Metalloprotease with ThromboSpondin type 1 member
13 (ADAMTS13) activity was determined to be severely low
at <5%, and ADAMTS13 inhibitor activity was <0.4 units.
Following discharge, the patient returned to the Emergency
Department two weeks later for fever of 38.4˚C and malaise,
however blood counts showed hemoglobin 9.8 g/dL, RDW
15.9%, platelet count 145 B/L, and serum creatinine 1.1 mg/dL,
so he was deemed stable for close follow-up as an outpatient.

Introduction
Congenital thrombotic thrombocytopenic purpura (CTTP),
also known as Upshaw-Schulman Syndrome (USS), is a very
rare, but potentially life-threatening disease. It is characterized
by the symptoms also seen in acquired or idiopathic TTP,
including thrombocytopenia, MAHA, and subsequent
microvascular thrombosis. However this constellation of
symptoms is seen in conjunction with significant and persistent
deficiency in ADAMTS13 with concurrent absence of an
ADAMTS13 inhibitor. ADAMTS13 is a protease responsible for
modifying the larger precursor of von Willebrand factor (vWF),
a necessary component of the clotting cascade. Continued
disruption of this process leads to microvascular embolization
and may ultimately cause potential end organ failure, including
heart, brain, and kidneys.

Historical Background
Cases concerning for CTTP were first reported in 1953, when
Dacie and colleagues described a 6-year-old female who suffered
repeated episodes of thrombocytopenia, hemolytic anemia,
presence of schistocytes, and significant jaundice since birth. The
young patient underwent splenectomy without improvement of
symptoms, and eventually died of renal failure at age 7. Upon
review of the patient’s family history, she had two other siblings,
who were jaundiced as newborns and both died of hemorrhage
by the age of 4. However the fourth child and both parents
were asymptomatic, so Dacie suspected that the patient and her
family had some yet to be determined inherited blood disorder.1
In 1960, Schulman reported an 8-year-old female who suffered
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from repeated bleeding episodes secondary to chronic thrombocytopenia and MAHA. Symptoms dramatically improved with
fresh frozen plasma (FFP), suggesting that the patient had a
congenital deficiency in some “platelet-stimulating factor.” 2
Upshaw and colleagues in 1978 would later report a 29-year-old
female who had repeated episodes of thrombocytopenia and
MAHA since childhood, that was treated with FFP.3
The syndrome for CTTP was coined by Rennard and Abe,
who recognized the similarities between the Upshaw and
Schulman’s cases, and they postulated that these patients
developed their sequelae as a result of increased fibronectin
during the symptomatic phase of their disease. 4 However,
multiple subsequent studies would later show there was no
association with fibronectin and disease activity.5,6,7 The assay
to assess ADAMTS13 activity was created in 1997, but it was
not until 2001 that the link between ADAMTS13 mutation and
subsequent deficiency and CTTP or USS was confirmed by Levy
and colleagues by means of linkage analysis performed on four
pedigrees with CTTP.8

Pathophysiology
USS is inherited through an autosomal recessive pattern,
though based upon clinical evaluation of USS patients, there
is a variable degree penetrance that does not necessarily follow
a structured genotype-phenotype correlation.9 It is caused by
mutations in the gene encoding ADAMTS13, and to date, there
have been 76 distinct reported mutations. 9 The majority of
these mutations are compound heterozygous in patients (64%
of reported USS cases), thereby making it difficult to connect
specific gene mutations to presentation characteristics of clinical
disease. However, it is noted that the majority of mutations
occur in the N-terminus portion of the protein, a sequence that
is responsible for encoding the domains specific to the metalloprotease activity function of ADAMTS13.9
USS, just as idiopathic or acquired TTP (ATTP), occurs as a
result of microthrombi formed from inappropriately formed
vWF precursor complexes, causing embolic ischemic damage
to end organs, typically heart, brain and kidney. Both are
usually prompted by stress-inducing triggers, such as infection
or pregnancy, but the etiology of microthrombi formation
differs as do the prognosis and recurrence risk. In ATTP,
microthrombi are formed as a result of auto-antibodies directed
towards ADAMTS13, thereby acting as an inhibitor to the
enzyme. In USS, an inherent deficiency in ADAMTS13 prevents
appropriate modification of the vWF precursor, allowing
formation of microthrombi.
VWF is a large glycoprotein produced in endothelial cells lining
the vasculature, and secreted in response to endothelial cell
activation or injury.9 It serves as an adhesion protein, recruiting
circulating platelets to collect at that activation site and form
a platelet plug. Just prior to platelet recruitment, vWF is
present in circulation as a larger multimeric precursor protein,
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ultra-large vWF (UL-vWF), of which ADAMTS13 immediately
cleaves into vWF for appropriate function in the clotting
cascade. In the absence of ADAMTS13, UL-vWF released from
vascular endothelial cells is not cleaved appropriately, which
induces platelet hyperagglutination under high shear stress.9
Uncleaved UL-vWF then binds to circulating platelets forming
microthrombi, which both embolize into the microvasculature
of end organs and cause fragmentation of adjacent circulating
erythrocytes, thereby producing MAHA.

Epidemiology
The incidence and prevalence of USS is extremely rare. It
is estimated that there have only been 100 cases worldwide
to date, with an incidence rate of no more than 1/1,000,000
person/year.9,10 USS comprises only 10% of all TTP patients with
known ADAMTS13 deficiency,11 Time of initial presentation
varies considerably; in one study of 43 USS patients in Japan,
age of onset ranged from early childhood to 79 years.12,13 With
regard to racial predilection, USS cases have been reported
in all continents, although there is an increased reported
incidence among patients of Japanese, Central European, and
Jamaican descent.9 The most commonly reported mutation
in ADAMTS13, c.4143dupA, was found through haplotype
analyses to have a common ancestral background stemming
from Central Europe. 14 A single nucleotide polymorphism
(SNP), specifically a p.P475S mutation, is reported to be
relatively common among the Japanese population, with 9.6%
of asymptomatic Japanese individuals being heterozygous for
that single mutation.15

Clinical Course
The classical presentation of USS is an initial episode of severe
neonatal jaundice with a negative Coombs test, requiring an
exchange blood transfusion, and repeated childhood episodes
of thrombocytopenia and MAHA, reversed by FFP, because of
the repletion of the deficient ADAMTS13 metalloprotease. 13
However this is a rare occurrence and the majority of USS have
a subclinical presentation, with significant variability in age of
onset and severity of presentation.13 Patients may present young
after typical childhood infections, during pregnancy, or even
late in adulthood despite having prior stress triggers. Although
patients who present early in life will likely have recurrent
episodes of overt TTP, even adult presenters are subject to
relapsing, recurrent disease.9 Presenting symptoms can range
from singular asymptomatic episodes of thrombocytopenia to
full-blown multi-organ failure and imminent death without
treatment.3,9
Given that patients with USS can often have delayed onset of
presentation and do not persistently manifest symptoms of overt
TTP despite chronic deficiency in ADAMTS13, one questions
the pathophysiology of the disease. Studies in ADAMTS13 gene
knock-out mice revealed the presence of circulating UL-vWF
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in the peripheral blood; however, these animal models did
not manifest acute symptoms of overt TTP. 16,17 Therefore,
it is assumed that disease activity operates under a “two-hit
hypothesis” in which the patient is chronically at increased
risk for TTP, compared to patients with normal ADAMTS13
activity, and can be considered as having a prothrombotic
predisposition. Overt disease will not usually manifest unless
instigated by a trigger or stress-inducing event, thereby
representing the “second hit.”13 At the level of the microvasculature, transient endothelial damage may occur, initiating the
release of inflammatory cytokines and thrombomodulin, setting
off a cascade heralding overt disease activity.18

Treatment
USS is initially treated in the same manner as ATTP, since
the diagnosis of USS is usually obtained after the patient has
already began treatment. Given the life-threatening and rapidly
progressive course of untreated TTP, the standard of care, plasma
exchange therapy, is immediately initiated upon the constellation
of symptoms: thrombocytopenia, MAHA, and presence of
schistocytes on peripheral smear. It is not appropriate to wait
for determination of ADAMTS13 activity prior to beginning
treatment. During plasma exchange, a venous-placed apheresis
catheter removes blood from the patient, separates the blood
cells from plasma, and returns the cells back while discarding the
plasma in exchange for new donor plasma. This serves to remove
the implicated autoantibody to ADAMTS13 in ATTP. However if
it is determined that the patient has USS, he or she can be treated
with FFP transfusions, which contain ADAMTS13, since the
etiology of overt TTP in this case is due to a lack of ADAMTS13
as opposed to inhibition of inherent ADAMTS13 activity.3
Given the chronic, subclinical nature of USS, patients should
receive expedited evaluation if they exhibit signs of infection,
trauma, pregnancy, or alterations in their neurologic or renal
function. Work-up should include a complete blood cell count
with differential, haptoglobin, LDH, and peripheral blood smear
to examine for schistocytes. Once determined that the USS
patient is having an episode of overt TTP, he or she can receive
FFP transfusions as well as erythrocyte and platelet transfusions
until platelets reach 140 B/L and LDH has corrected to within
normal range.
Additional developments in more curative forms of treatment
for USS are currently under investigation. A recombinant human
ADAMTS13 enzyme has been developed to correct deficiencies
in vWF cleaving activity in vitro, as well as early studies in using
monoclonal antibody rituximab for definitive therapy.19
Summary (a potential consideration in patients with progressive
microangiopathic disease of brain, kidney unknown etiology)
USS, though very rare, is a chronic progressive disease that can
easily become life-threatening without proper early recognition
and treatment. Once diagnosed with USS, management should
focus on preventative measures and early evaluation at the onset
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of disease triggers.3 Given the asymptomatic nature of the disease
when the patient is in his or her normal state of health, it is safer
and more cost-effective to treat with plasma transfusions and
exchange therapy as needed only when symptoms arise, rather
than scheduled sessions of transfusion treatment. However, this
places the onus of responsibility on patients and their families.
They must be educated on USS manifestations and motivated to
pursue early evaluation as well as routine medical assessments
for renal and neurologic abnormalities, which may signal an
acutely developing disease.3
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